Ichnos Glenmark Innovation Unveils First-in-Class Multispecific Cancer Drug ISB 2301 for Solid Tumors
核心洞察
Ichnos Glenmark Innovation (搜索) has announced ISB 2301, a first-in-class multispecific immune cell activator targeting three tumor-associated antigens (搜索) simultaneously for solid tumor treatment.
The drug candidate engages both T cells (搜索) and NK cells to activate the immune system while inducing antibody-dependent cellular cytotoxicity and checkpoint inhibition.
ISB 2301 was developed using IGI's proprietary BEAT platform technology and is designed to address the biological complexity of solid tumors (搜索) that conventional immunotherapies have struggled with.
Ichnos Glenmark Innovation (搜索), Inc. (IGI), a global clinical-stage biotechnology company focused on developing multispecific antibodies in oncology, has announced ISB 2301, a novel development candidate for the potential treatment of multiple solid tumor indications. The first-in-class multispecific immune cell activator represents a significant advancement in precision cancer (搜索) treatment approaches.
Novel Tri-Targeting Mechanism
ISB 2301 employs a sophisticated mechanism that simultaneously targets three tumor-associated antigens (搜索) to trigger tumor cell death while engaging both T cells (搜索) and natural killer (NK) cells to activate the immune system. This multi-pronged approach is designed to overcome the biological complexity that has challenged conventional immunotherapies in solid tumor treatment.
The drug candidate is engineered to induce antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and a sustained type-1 immune response. This comprehensive mechanism represents what the company believes sets a new benchmark for multispecific antibody capabilities in solid tumors (搜索).
BEAT Platform Technology
ISB 2301 was developed using IGI's proprietary BEAT platform technology, which enables the combination of multiple tumor-attacking mechanisms. The platform allows the drug to deliver antibody action, block cancer (搜索) defenses, and maintain sustained immune responses simultaneously.
"We engineered ISB 2301 to match the biological complexity of solid tumours in a way that conventional immunotherapies have not been able to address," said Lida Pacaud, MD, President and Chief Executive Officer of IGI. "By simultaneously targeting three tumour-associated antigens and engaging both T cells (搜索) and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumours."
Clinical Development Timeline
IGI has outlined an ambitious timeline for bringing ISB 2301 to clinical testing. The company intends to file an Investigational New Drug (IND) application by the end of 2026, with clinical studies planned to begin in 2027. This timeline reflects the company's confidence in the preclinical development progress of the candidate.
Corporate Structure and Market Impact
Glenmark Pharmaceuticals Limited informed stock exchanges about the development through a regulatory filing, highlighting the significance of this advancement for the parent company's oncology portfolio. Following the announcement, shares of Glenmark Pharma closed at ₹2,370 on the NSE, down ₹35.90 or 1.49% from the previous close, reflecting typical market volatility around early-stage drug announcements.
The development of ISB 2301 represents IGI's commitment to addressing unmet medical needs in solid tumor treatment through innovative multispecific antibody approaches that leverage the body's natural immune mechanisms.